Skip to main
APYX

APYX Stock Forecast & Price Target

APYX Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Apyx Medical Corp is poised for growth, with Surgical Aesthetics revenue projected to reach between $43.0 million and $45.0 million, reflecting a year-over-year increase of 14% at the midpoint and a positive revision in full-year revenue guidance to $50.5 million to $52.5 million. The recent launch of the AYON system and the resulting 19% uptick in Surgical Aesthetics revenue, alongside increased demand for skin tightening procedures linked to weight-loss trends, further support a favorable financial outlook. Additionally, Apyx's revenue estimates for FY2026 have been raised to $58.0 million, indicating a strong market position fueled by innovation and shifting consumer needs.

Bears say

Apyx Medical Corp has revised its Original Equipment Manufacturing (OEM) sales guidance down to approximately $7.5 million, reflecting a decline of around $0.5 million from previous projections, primarily attributed to reduced sales volumes to existing customers. The company's stock price has struggled since peaking at $17.40 per share in September 2021, largely due to the lingering effects of an FDA warning letter issued in March 2022 and heightened competition in the aesthetic medicine sector driven by the increasing use of GLP-1 medications. Additionally, Apyx Medical's financial position shows a decrease in cash and cash equivalents, falling to $25.1 million at the end of Q3 2025 from $29.3 million in Q2 2025, which raises concerns regarding operational liquidity amid revenue pressures.

APYX has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Apyx Medical Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Apyx Medical Corp (APYX) Forecast

Analysts have given APYX a Strong Buy based on their latest research and market trends.

According to 4 analysts, APYX has a Strong Buy consensus rating as of Mar 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Apyx Medical Corp (APYX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.